Kyverna Therapeutics shares surged 5.77% in pre-market trading driven by momentum from J.P. Morgan Healthcare Conference presentation.

Kyverna Therapeutics surged 5.7737% in pre-market trading on January 15, 2026, driven by momentum from its recent J.P. Morgan Healthcare Conference presentation. The biotech firm highlighted robust clinical data for its CAR T therapy, Miv-cel, in treating stiff person syndrome (SPS) and myasthenia gravis (MG). Trial results showed statistically significant improvements in mobility and elimination of off-label immunotherapies, with a clear regulatory path to a Biologics License Application (BLA) filing in the first half of 2026.

Analysts noted Kyverna’s strengthened financial position, with cash reserves extending through 2028, and its positioning as a first-to-market leader in SPS. The company’s presentation emphasized its ability to execute on clinical enrollment and meet unmet medical needs, supported by Orphan Drug and Regenerative Medicine Advanced Therapy designations. These factors, combined with positive trial endpoints across multiple metrics, underscore investor confidence in Kyverna’s pipeline and commercial potential.